Skip to main content
BrainCited

[Pharmacological prevention of cognitive decline and dementia].

Frank Jessen
Review Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 2020 4 citations
PubMed DOI
<\/script>\n
`; }, get iframeSnippet() { const domain = 'braincited.com'; const params = 'pmid\u003D32185450'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

Study Design

Type d'étude
Review
Population
Alzheimer's disease patients
Intervention
[Pharmacological prevention of cognitive decline and dementia]. None
Comparateur
None
Critère de jugement principal
None
Direction de l'effet
Mixed
Risque de biais
Unclear

Abstract

BACKGROUND: Dementias are among the most feared diseases and pose a threat to social and healthcare systems in aging societies. A cure for Alzheimer's or other dementias will not be achieved in the coming years, which makes prevention of cognitive decline and dementia a priority for research and patient-related services. AIM: Summary of evidence for drug and other compound-related prevention of cognitive decline and dementia. MATERIAL AND METHODS: Literature review of epidemiological evidence and clinical trials of antidementia drugs, anti-amyloid drugs under development, nonsteroidal anti-inflammatory drugs, statins, hormone replacement therapy, lithium, ginkgo biloba, and Fortasyn Connect. RESULTS: There is evidence for effects on single endpoints and subgroups for some of the reviewed compounds, but there is no consistent evidence for efficacy. DISCUSSION: There is no sufficient evidence to provide any specific or general recommendation for drug- or compound-related prevention of cognitive decline or dementia. It needs to be recognized that prevention trials on cognitive decline in aging and dementia require large numbers of participants and long follow-up times, which create major challenges with regard to conducting and financing such trials. The current state of evidence also supports the potential role of nonpharmacological approaches in dementia prevention.

En bref

The current state of evidence also supports the potential role of nonpharmacological approaches in dementia prevention and there is evidence for effects on single endpoints and subgroups for some of the reviewed compounds.

Used In Evidence Reviews

Similar Papers